Abstract: The invention provides isolated nucleic acid compounds encoding the stem peptide biosynthetic gene ddl of Streptococcus pneumoniae. Also provided are vectors and transformed heterologous host cells for expressing the DDL enzyme product and a method for identifying compounds that inhibit stem peptide biosynthesis.
Abstract: The invention provides isolated nucleic acid compounds encoding a multiple drug resistance protein of Aspergillus flavus. Vectors and transformed host cells comprising the multiple drug resistance-encoding DNA of Aspergillus flavus MDR-1 are also provided. The invention further provides assays which utilize these transformed host cells.
Abstract: The invention provides isolated nucleic acid compounds encoding the stem peptide biosynthetic gene murA of Streptococcus pneumoniae. Also provided are vectors and transformed heterologous host cells for expressing the MurA enzyme product and a method for identifying compounds that inhibit stem peptide biosynthesis.
Abstract: The invention provides isolated nucleic acid compounds encoding the murE stem peptide biosynthetic gene of Streptococcus pneumoniae. Also provided are vectors and transformed heterologous host cells for expressing the murE enzyme product and a method for identifying compounds that inhibit stem peptide biosynthesis.
Type:
Grant
Filed:
May 29, 1996
Date of Patent:
January 27, 1998
Assignee:
Eli Lilly and Company
Inventors:
Robert Brown Peery, Paul Luther Skatrud
Abstract: The present invention provides isolated DNA compounds and recombinant DNA vectors that encode mammalian influx peptide transporter activity. The invention also provides host cells transformed with these vectors and a method for production of mammalian influx peptide transporter activity by recombinant DNA techniques. The invention also provides a method for identifying compounds that are transported into the cell by the influx peptide transporter.
Type:
Grant
Filed:
June 5, 1995
Date of Patent:
January 20, 1998
Assignee:
Eli Lilly and Company
Inventors:
Anne H. Dantzig, Jo Ann Hoskins, Paul L. Skatrud
Abstract: The invention provides isolated nucleic acid compounds encoding a multiple drug resistance protein of Aspergillus fumigatus. Vectors and transformed host cells comprising the multiple drug resistance-encoding DNA of Aspergillus fumigatus MDR-1 are also provided. The invention further provides assays which utilize these transformed host cells.
Abstract: This invention describes a novel human serotonin receptor, designated 5-HT.sub.2B. This invention also encompasses nucleic acids encoding this receptor, or a fragment thereof, as well as methods employing this receptor and the nucleic acid compounds.
Abstract: The invention provides isolated nucleic acid compounds encoding the stem peptide biosynthetic gene murA of Streptococcus pneumoniae. Also provided are vectors and transformed heterologous host cells for expressing the MurA enzyme product and a method for identifying compounds that inhibit stem peptide biosynthesis.
Abstract: The invention provides isolated nucleic acid compounds encoding the murD stem peptide biosynthetic gene of Streptococcus pneumoniae. Also provided are vectors and transformed heterologous host cells for expressing the MurD enzyme product and a method for identifying compounds that inhibit stem peptide biosynthesis.
Type:
Grant
Filed:
June 18, 1996
Date of Patent:
October 28, 1997
Assignee:
Eli Lilly and Company
Inventors:
Jo Ann Hoskins, Robert Brown Peery, Paul Luther Skatrud, Chyun-Yeh Earnest Wu
Abstract: Heterologous extra-cellular expression of recombinant proteins in soluble functional form is desirable because of the ease associated with purification of the secreted proteins and avoidance of the need for cell extraction and protein refolding procedures. The present invention provides DNA sequences of the naturally-occurring phthalyl amidase gene isolated from Xanthobacter agilis that control transcription, translation, and extra-cellular secretion of proteins in Streptomyces lividans. These DNA sequences can be used in a method for extra-cellular expression of a wide variety of proteins in soluble functional form.
Abstract: The present invention provides isolated DNA compounds and recombinant DNA vectors that encode mammalian influx peptide transporter activity. The invention also provides host cells transformed with these vectors and a method for production of mammalian influx peptide transporter activity by recombinant DNA techniques. The invention also provides a method for identifying compounds that are transported into the cell by the influx peptide transporter.
Type:
Grant
Filed:
May 1, 1995
Date of Patent:
April 15, 1997
Assignee:
Eli Lilly and Company
Inventors:
Anne H. Dantzig, Jo A. Hoskins, Paul L. Skatrud